Amicogen Inc operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amicogen Inc with three other
companies in this sector in KOREA (SOUTH) :
CKD Bio Corp
sales of 124.60 billion Korean Won [US$111.39 million]
of which 33%
was Potassium Clavulanate),
Samil Pharmaceutical Co., Ltd.
(123.00 billion Korean Won [US$109.96 million]
Hwail Pharmaceutical Company Limited
(123.61 billion Korean Won [US$110.51 million]
During the first
quarter of 2021, sales at Amicogen Inc totalled
30.65 billion Korean Won .
an increase of 21.5%
from the 25.23 billion Korean Won in sales at the company during the first quarter of 2020.
There appears to be at least some degree of seasonality in the sales at Amicogen Inc: during 7 of the previous 8
years, sales were highest during the fourth quarter.
The exception to this was during 2018, when the
first quarter was the best quarter, accounting for
31% of sales (during that same year, the
fourth quarter accounted for 21% of sales).
Amicogen Inc reported sales of 115.86 billion Korean Won (US$103.58 million)
December of 2020.
a very small
increase of 0.6%
versus 2019, when the company's sales were 115.18 billion Korean Won .
Sales at Amicogen Inc have increased during each of the previous five years
(and since 2015, sales have increased a total of 257%).